In a report released yesterday, Anthony Vendetti from Maxim Group maintained a Buy rating on Venus Concept (VERO – Research Report), with a price target of $0.75. The company’s shares closed yesterday at $0.22.
Vendetti covers the Healthcare sector, focusing on stocks such as Venus Concept, Nephros, and Biolase. According to TipRanks, Vendetti has an average return of -4.5% and a 31.97% success rate on recommended stocks.
Venus Concept has an analyst consensus of Moderate Buy, with a price target consensus of $0.88, implying a 300.73% upside from current levels. In a report released yesterday, BTIG also maintained a Buy rating on the stock with a $1.00 price target.
See today’s best-performing stocks on TipRanks >>
VERO market cap is currently $13.88M and has a P/E ratio of -0.35.
Based on the recent corporate insider activity of 16 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of VERO in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Venus Concept, Inc. is a medical aesthetic technology company. Its product portfolio consists of aesthetic device platforms which includes venus versa, venus legacy, venus velocity, venus fiore, venus viva, venus freeze plus, and venus bliss. The company was founded in 2002 and is headquartered in Toronto, Canada.
Read More on VERO:
